Celgene, Barr Resolve Spat Over Generic Thalomid

Law360, New York (May 26, 2010, 7:34 PM EDT) -- Pharmaceutical company Celgene Corp. and generic-drug maker Barr Laboratories Inc. have resolved their dispute over generic competition for the cancer drug Thalomid, with Celgene agreeing to drop its patent infringement claims and Barr shedding its invalidity and antitrust allegations.

Judge Susan D. Wigenton of the U.S. District Court for the District of New Jersey on Wednesday approved the parties' stipulation of dismissal without prejudice of all claims and counterclaims asserted in four consolidated actions over Barr's attempt to market a generic version of the drug before...
To view the full article, register now.